The trial involved 30 patients who had been diagnosed with either T2-high or T2-low severe asthma. Patients were evaluated at baseline and subsequently after 4 weeks of tezepelumab add-on therapy. The clinical symptom control, asthma-related quality of life, lung function, inflammatory biomarkers, and use of oral corticosteroid (OCS) were among the assessments. The participants were recruited from a single centre and comprised those who had and had not received prior treatment with other biologic drugs.
Markers of inflammation also showed significant reductions. Fractional exhaled nitric oxide (FeNO), the eosinophilic airway inflammation biomarker, declined significantly. Counts of blood basophils, another indicator of allergic and inflammatory reaction, also decreased. In cytokines, serum levels of interleukin-2 (IL-2) and vascular endothelial growth factor (VEGF) were significantly decreased, evidencing the extensive immunomodulatory actions of tezepelumab.
Key Findings
• 30 patients with severe asthma were assessed
• Substantial symptom improvement quantified by ACT score and AQLQ
• Improved lung function: FEV1, FEF25–75, and Rtot
• Reduced inflammatory markers: FeNO, basophil count
• Decreased cytokines: IL-2, VEGF
• Effects observed in both T2-high and T2-low patients
• Beneficial regardless of previous biologic use
Efficacy Across Asthma Phenotypes
Significantly, the study confirmed that the benefits of tezepelumab extended to both T2-high and T2-low phenotypes of severe asthma. In addition, the drug's efficacy was unaffected in patients whether they had been exposed to prior use of other biologic medicines or not. This highlights tezepelumab's sole strength: it neither depends on eosinophilic nor allergic biomarkers to act on patients with severe asthma. Hence, it is a therapy universally applicable across all cases of severe asthma.
In this real-world investigation, tezepelumab demonstrated rapid and robust improvements in asthma control, lung function, and inflammatory markers for both T2-high and T2-low phenotypes. Its efficacy, irrespective of previous biologic exposure, attests to its utility as a useful add-on treatment with widespread use in severe asthma. Future long-term research may further confirm such encouraging initial findings and optimize its placement within asthma treatment guidelines.
Reference:
Pelaia, C., Greco, M., Iaccino, E., Crimi, C., Biafora, M., Dragone, F., Vatrella, A., & Pelaia, G. (2025). Short-term therapeutic effectiveness of tezepelumab in patients with severe asthma: A real-world study. International Immunopharmacology, 162(115185), 115185. https://doi.org/10.1016/j.intimp.2025.115185
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.